2024-12-24 09:33:57
DEBIOPHARM ANNOUNCES LAUNCH OF THE PHASE 1/2 GaLuCi™ STUDY FOR ITS CA IX-TARGETED RADIOPHARMACEUTICAL PROGRAM
Health/ 2023-07-22
DEBIOPHARM ANNOUNCES LAUNCH OF THE PHASE...

Debiopharm is developing personalized radiotherapy through a theranostic approach,combining diagnostic imaging (Debio 0328a gallium-labelled...

3SBio announces 2022 annual results, with revenue rising 7.5% year on year and normalized net profit attributable to parents jumping 25.2%
Corporate/ 2023-07-24
3SBio announces 2022 annual results, wit...

HONG KONG,March 22,2023--Chinese leading biopharmaceutical company 3SBio (01530.HK) today announced its 2022 annual results. In 2022,3SBio\'...

CUSMail

CusMail provide the Latest News , Business and Technology News Release service. Most of our news is paid for distribution to meet global marketing needs. We can provide you with global market support.

© CUSMAIL. All Rights Reserved. Operate by Paid Release